Amag Pharmaceuticals inc (AMAG) |
|
Price: $0.0000
$0.00
%
|
Day's High:
| 0.00
| Week Perf:
|
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
35 |
Employees |
650 |
Revenues (TTM) (Millions $) |
303 |
Net Income (TTM) (Millions $) |
-182 |
Cash Flow (TTM) (Millions $) |
-155 |
Capital Exp. (TTM) (Millions $) |
0 |
Amag Pharmaceuticals Inc
Amag Pharmaceuticals Inc. is a publicly-traded biopharmaceutical company headquartered in Waltham, Massachusetts. It was founded in 1981 and is focused on developing innovative therapies to improve patients' lives.
Amag Pharmaceuticals Inc. has a diverse product portfolio that includes drugs for the treatment of various medical conditions. The company's core therapeutic areas are women's health, anemia, and cancer supportive care.
One of Amag's flagship products is Makena, a hormone injection used to prevent preterm birth in women who have a history of preterm birth. The company acquired the rights to Makena from Hologic in 2014, and it has been a significant contributor to Amag's revenue since then.
The company also has two FDA-approved drugs, Feraheme and MuGard, that are used to treat iron deficiency anemia and the oral mucositis associated with chemotherapy and radiation, respectively.
In addition to its marketed products, Amag Pharmaceuticals is also engaged in research and development of new medicines. The company has a robust pipeline that comprises several promising drugs at various stages of development.
AMAG-423, for example, is an investigational therapy that is being evaluated for the treatment of severe preeclampsia, a potentially life-threatening pregnancy complication. Another compound, Vyleesi, is a self-administered injection that is being developed to address hypoactive sexual desire disorder in women.
The company's research and development efforts also include exploring the potential of the synthetic lactoferrin protein to treat iron deficiency anemia, as well as innovative technologies for drug delivery and formulation.
Overall, Amag Pharmaceuticals Inc. is a research-driven pharmaceutical company that is committed to developing innovative therapies for significant, unmet medical needs. The company's key strengths lie in women's health, anemia, and cancer supportive care, and it leverages its expertise in these areas to drive innovation and value for patients and investors alike.
Company Address: 1100 Winter Street, Waltham, 2451 MA
Company Phone Number: 498-3300 Stock Exchange / Ticker: NASDAQ AMAG
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Altimmune Inc
Altimmune Inc., a clinical-stage biopharmaceutical company, has recently reported its financial results for the three months ending December 31, 2023. It recorded a loss per share of $-0.50, which is an increase from the loss of $-0.46 per share in the previous year's reporting period. In the preceding reporting period, Altimmune Inc. realized a loss per share of $-0.39. Alongside this, the company witnessed a significant decline in revenue, with a decrease of -89.779% from $0.36 million to an alarming level. This decline in revenue was accompanied by a surge in losses. The net loss for the fourth quarter of 2023 amounted to $-31.641 million, higher than the $-21.660 million reported in the same quarter a year ago. Additionally, Altimmune Inc. reported a net deficit of $-88.45 million for the 2023 financial year, with revenue reaching just $0.43 million.
|
Cellectar Biosciences Inc
Cellectar Biosciences Inc, a late-stage clinical biopharmaceutical company focused on cancer treatment, has seen its stock rise by 20.9% over the last five trading days. This significant increase in stock value indicates a positive market sentiment towards the company. Moreover, over the past 12 months, the stock has shown a continuous upward trend, coming within 9% of its 52-week high. These positive market indicators could be attributed to recent developments within the company. Cellectar Biosciences announced through a press release that it has achieved positive findings from an investigator-initiated Phase 1 study. The study evaluated the safety and efficacy of Iopofosine in combination with external beam radiotherapy (EBRT) for the treatment of recurrent head and neck cancer. This groundbreaking research has created a sense of hope for both patients and healthcare professionals who are seeking improved therapeutic options for this challenging disease.
|
Glycomimetics Inc
GlycoMimetics, a prominent biotechnology company headquartered in Rockville, Maryland, recently made headlines with the approval of an inducement grant for its new Senior Vice President, Dr. Shantha Tyavanagimatt. This article delves into the details of the grant and its potential implications on GlycoMimetics' shares. Additionally, we will analyze the recent performance of Glycomimetics Inc shares and provide context to understand the broader market trends. Grant Approval: On February 6, 2024, GlycoMimetics' Compensation Committee granted Dr. Shantha Tyavanagimatt an option to purchase 130,000 shares of the company's common stock. This inducement equity award aims to attract and retain highly qualified professionals in crucial leadership positions, thereby strengthening GlycoMimetics' technical operations.
|
Ampio Pharmaceuticals Inc
Investors have been pleasantly surprised by recent developments in the stock market, particularly in the healthcare sector. Ampio Pharmaceuticals Inc. (AMPE) has showcased encouraging numbers during the October to December 2023 earnings season. Despite expectations of no significant changes at the top-line, the company's operating loss has improved, hinting at a positive trajectory for future success. Shareholders and market participants are gaining confidence in AMPE's potential, and these promising developments are worth exploring in detail. Operating Loss Improvement: During the same period, AMPE displayed a noteworthy reduction in operating loss, from $-2.702 million in Q4 of 2022 to $-2.215 million currently. While it may not be the easiest benchmark, this improvement is substantial and indicative of the company's commitment to growth and stability. Moreover, the company has further narrowed the losses from $-2.220 million to $-2.054 million quarter-on-quarter, boosting expectations of its future performance.
|
Vaxxinity Inc
The Major Pharmaceutical Preparations sector researchers have recently begun analyzing the fourth quarter performance of 2023. One company in particular, Vaxxinity Inc, has caught their attention due to its operating shortfall of $-25.05 million for the period. It is worth noting that Vaxxinity Inc has not yet reported its top-line figures for this reporting season. To provide some context, let's compare this performance to the previous year. In the fourth quarter of 2022, Vaxxinity Inc reported an operating shortfall of $-20.823 million. This suggests a slight increase in the operating shortfall for the current period. The company's CFO is working on implementing different corporate policies to ensure a steady revenue source.
|
Per Share |
Current |
Earnings (TTM) |
-6.76 $ |
Revenues (TTM) |
8.73 $
|
Cash Flow (TTM) |
- |
Cash |
4.86 $
|
Book Value |
7.37 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-6.76 $
|
Revenues (TTM) |
8.73 $ |
Cash Flow (TTM) |
- |
Cash |
4.86 $
|
Book Value |
7.37 $ |
Dividend (TTM) |
0 $ |
|
|
|
|